tosufloxacin has been researched along with clarithromycin in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (33.33) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hirayama, F; Ikeda, Y; Kawakita, T; Kuroda, T; Moriguchi, A; Sakurai, N; Sano, M; Uemori, S; Yamamoto, K | 1 |
Bryan, JP; Sheffield, J; Wagner, KF; Waters, C | 1 |
Hashido, H; Ishigo, S; Iwata, I; Matsubara, S; Matsukawa, Y; Mikamo, H; Sawamura, H; Suematsu, H; Tamaya, T | 1 |
Friedman, H; Yamaguchi, H; Yamamoto, M; Yamamoto, Y; Yasuda, K | 1 |
Akaike, H; Kato, A; Kawai, Y; Kawasaki, K; Kondo, E; Kubo, M; Miyashita, N; Nakano, T; Nishizawa, Y; Ogita, S; Ouchi, K; Saito, A; Tanaka, T; Terada, K; Teranishi, H | 1 |
Aoyagi, H; Ariga, T; Furuyama, H; Hara, K; Hazama, K; Horino, A; Ishiguro, N; Ishizaka, A; Kaiho, M; Kenri, T; Kikuta, H; Koseki, N; Morita, K; Nagano, N; Naito, H; Nakanishi, M; Oba, K; Sasaki, S; Shibata, M; Shida, S; Tabata, Y; Togashi, T; Watanabe, T; Yamanaka, T; Yoshioka, M | 1 |
1 trial(s) available for tosufloxacin and clarithromycin
Article | Year |
---|---|
Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients.
Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Child; Child, Preschool; Clarithromycin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Infant; Infant, Newborn; Male; Minocycline; Mutation; Mycoplasma pneumoniae; Naphthyridines; Pneumonia, Mycoplasma; RNA, Bacterial; RNA, Ribosomal, 23S; Treatment Outcome | 2013 |
5 other study(ies) available for tosufloxacin and clarithromycin
Article | Year |
---|---|
Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Drug Stability; Fluoroquinolones; Gerbillinae; Helicobacter Infections; Helicobacter pylori; Indicators and Reagents; Microbial Sensitivity Tests; Molecular Structure; Naphthyridines; Ofloxacin; Quinolones; Solutions; Structure-Activity Relationship; Ultraviolet Rays | 1998 |
In vitro activity of tosufloxacin (A-60969) and clarithromycin (A-56268, TE-031) against resistant Haemophilus influenzae, Streptococcus pneumoniae and Branhamella catarrhalis isolates.
Topics: 4-Quinolones; Anti-Infective Agents; Clarithromycin; Drug Resistance, Microbial; Erythromycin; Fluoroquinolones; Haemophilus influenzae; In Vitro Techniques; Microbial Sensitivity Tests; Moraxella catarrhalis; Naphthyridines; Streptococcus pneumoniae | 1990 |
[The frequency of Streptococcus pneumoniae strains and sensitivity surveillance for several antibiotics in Gifu Prefecture].
Topics: Amoxicillin; Anti-Bacterial Agents; Cefaclor; Cefdinir; Cefixime; Cefmenoxime; Cefpodoxime; Ceftizoxime; Cephalosporins; Ciprofloxacin; Clarithromycin; Clindamycin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Imipenem; Japan; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Minocycline; Naphthyridines; Ofloxacin; Penicillin G; Penicillins; Streptococcus pneumoniae; Thienamycins | 2000 |
Chlamydia pneumoniae resists antibiotics in lymphocytes.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cells, Cultured; Chlamydia Infections; Chlamydophila pneumoniae; Clarithromycin; Female; Fluoroquinolones; Humans; Lymphocytes; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Minocycline; Naphthyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Bacterial | 2003 |
Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients.
Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Child; Clarithromycin; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Minocycline; Mycoplasma pneumoniae; Naphthyridines; Pneumonia, Mycoplasma; Treatment Outcome | 2017 |